Drugs / ODM-104
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT04571996 | Oct 2020 → Feb 2021 | central nervous system disorder | Orion Corporation, Orion Pharma | Completed | No outcome recorded |
| Phase 1 | NCT03140956 | Apr → Jul 2017 | Parkinson disease | Orion Corporation, Orion Pharma | Completed | No outcome recorded |
| Phase 1 | NCT03055936 | Feb → Jun 2017 | — | Orion Corporation, Orion Pharma | Completed | No outcome recorded |
| Phase 1 | NCT02554734 | Aug → Nov 2015 | Parkinson disease | Orion Corporation, Orion Pharma | Completed | No outcome recorded |
| Phase 1 | NCT02312232 | Nov 2014 → Feb 2015 | Parkinson disease | Orion Corporation, Orion Pharma | Completed | No outcome recorded |
| Phase 1 | NCT01840423 | May 2013 → Dec 2014 | — | Orion Corporation, Orion Pharma | Completed | No outcome recorded |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT02764125 | Apr 2016 → Mar 2018 | Parkinson disease | Orion Corporation, Orion Pharma | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ODM-104 | “Levodopa MR/carbidopa/ODM-104” NCT02764125 ↗ |
| Route | Oral | “Oral capsules dosage 10-800mg once daily for one day or three times daily for 7 days” NCT01840423 ↗ |